Featured Research

from universities, journals, and other organizations

New model to study schizophrenia and other neurological conditions

Date:

August 30, 2013

Source:

Salk Institute for Biological Studies

Summary:

Schizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top ten causes of disability in developed countries.

Share This

chizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top ten causes of disability in developed countries.

Related Articles

Now, in this week's issue of the Proceedings of the National Academy of Sciences, Thomas Albright and Ricardo Gil-da-Costa of the Salk Institute for Biological Studies describe a model system that completes the bridge between cellular and human studies of schizophrenia, an advance that should help speed the development of therapeutics for schizophrenia and other neurological disorders.

"Part of the terror of schizophrenia is that the brain can't properly integrate sensory information, so the world is a disorientating series of unrelated bits of input," says Albright, the Conrad T. Prebys Chair in Vision Research. "We've created a model that tests the ability to do sensory integration, which should be extremely useful for pharmaceutical research."

Currently, over 1.1 percent of the world's population has schizophrenia, with an estimated three million individuals in the United States alone. The economic cost is high: In 2002, Americans spent nearly $63 billion on treatment and managing disability. The emotional cost is higher still: Ten percent of those with schizophrenia are driven to commit suicide by the burden of coping with the disease.

Initially, it was thought that excessive amounts of the neurotransmitter dopamine caused psychotic symptoms, and indeed, current anti-psychotic drugs work by blocking dopamine from entering brain cells. But nearly all of these drugs have severe cognitive side effects, which led researchers to speculate that some other mechanism must also be involved.

A major clue to understanding schizophrenia came with the development of phencyclidine (PCP) in 1956. It was intended to keep patients safely asleep during surgeries, but many woke up with symptoms similar to those experienced by people with schizophrenia, including hallucinations and the disorientation of feeling "dissociated" from their limbs, resulting in PCP being abandoned for clinical purposes. A decade later, it was replaced by a derivative called ketamine. At doses high enough to put patients to sleep, ketamine is an effective anesthetic. At lower doses, it temporarily produces the same schizophrenia-like effects as PCP.

The two drugs are part of a class called N-methyl-D-aspartate receptor antagonists. Essentially, they work by gumming up the mechanism by which glutamate, the main excitatory neurotransmitter, would enter brain cells. Thus, it is clear that dopamine dysfunction accounts for some of the symptoms of psychosis, although that is probably not the full story.

"While dopamine has limited reach in the brain, any dysfunction in glutamate would be expected to have the sort of widespread effects we see in the perceptual disorders associated with schizophrenia," says Albright. "Nevertheless, which neurotransmitter was primary to these disorders -- -glutamate or dopamine -- -- has been argued about for years."

Standing in the way of a definitive answer was a researcher's Catch-22: Many experiments designed to understand cognitive disorders such as schizophrenia or Alzheimer's require a participant's conscious attention-yet these disorders interfere with attention.

To get around this, scientists turned to electroencephalograms (EEGs), which can be used to detect changes in cases where a subject is not consciously paying attention to a stimulus, by recording the brain's electrical signals through electrodes placed in a scalp cap. In one test, a series of tones is played, but an "oddball" tone breaks the pattern in the sequence. A healthy brain can still easily spot the differences, even if a participant is concentrating on another task, such as reading a magazine.

"The test works because the brain is a prediction machine-it's built to anticipate what should come next," says Albright. "If you have healthy working memory, you should be able to perceive a pattern and notice when something violates it, but patients suffering from some mental health disorders lack that basic ability."

In their latest research, Albright's team detected the difference through two signals, event-related brain potentials called mismatch negativity (MMN) and P3. The MMN reflects differential brain activity to the detected oddball tone, below the level of conscious awareness. P3 picks up the next phase: a subject's attention orientation to the oddball tone.

Still, a gap in understanding remained. While scientists could do cellular work in animal models on the role of dopamine versus glutamate, and they could do EEGs in human beings, a bridge between the two remained elusive. Such a bridge can help scientists understanding of how healthy and disordered brains work from the cellular level all the way to the multiple interactions between brain areas. Moreover, it can enable pre-clinical and clinical trials linking cellular and systems levels for successful therapeutic avenues.

Gil-da-Costa has at last crossed the bridge by crafting the first non-invasive scalp EEG setup that records accurately from the brains of non-human primates, with the same proportional density of electrodes as a human cap and no distortions in signal caused by an incorrect fit. This setup allows him to get accurate measurements of MMN and P3, with the same protocols that are followed in humans. As a result, the lab has come closer than ever before to untangling the roles of dopamine and glutamate.

"While rodents are essential for understanding mechanisms at a cellular or molecular level, at a higher cognitive level, the best you could do was a sort of rough analogy. Now, finally, we can have a one-to-one correspondence," says Gil-da-Costa. "For sensory integration, our findings with this model support the glutamate hypothesis."

Pharmaceutical companies are interested in the model, because of the potential for more precise testing and the universality of the MMN/P3 assays. "These brain makers are the same across dozens of neurological diseases, as well as brain trauma, so you can test potential therapies not just for schizophrenia, but for conditions such as Parkinson's, Alzheimer's, bi-polar disorder, and traumatic brain injuries," says Gil-da-Costa. "We hope this will help begin a new era in neurological therapeutics."

Other researchers on the study were Gene R. Stoner and Raynard Fung of the Salk Institute for Biological Studies.

Salk Institute for Biological Studies. (2013, August 30). New model to study schizophrenia and other neurological conditions. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2013/08/130830091620.htm

More From ScienceDaily

More Mind & Brain News

Featured Research

Mar. 31, 2015 — In addition to their physical injuries, women who are victims of domestic violence are also at a greater risk of mental health problems such as depression and psychotic symptoms. "We studied the ... full story

Mar. 31, 2015 — A unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome have been discovered, providing insights into the basis for cognitive ... full story

Mar. 31, 2015 — Children who get a taste of their parents' wine now and then may be more likely than their peers to start drinking by high school, according to a new report. The findings are based on 561 Rhode ... full story

Mar. 30, 2015 — Neuroscientists are taking inspiration from natural motor control to design new prosthetic devices that can better replace limb function. Researchers have tested a range of brain-controlled devices ... full story

Mar. 30, 2015 — Speaking in public is the top fear for many people. Now, researchers have developed an intelligent user interface for 'smart glasses' that gives real-time feedback to the speaker on volume modulation ... full story

Mar. 30, 2015 — To help scientists make sense of 'brain big data,' researchers have used data mining to create www.neuroelectro.org, a publicly available website that acts like Wikipedia, indexing physiological ... full story

Mar. 30, 2015 — The moon does not influence the timing of human births or hospital admissions, a new study finds, confirming what astronomers have known for decades. The study illustrates how intelligent people ... full story

Mar. 30, 2015 — An estimated eight million adults in the U.S. suffer from binge eating disorder. Now, researchers have shown that compulsive binging on foods that are high in fat and sugar can trigger specific ... full story

Mar. 30, 2015 — New estimates suggest that 20 to 30 percent of opioid analgesic drugs prescribed for chronic pain are misused, while the rate of opioid addiction is approximately 10 percent. "On average, misuse was ... full story

Featured Videos

AAA: Distracted Driving a Serious Teen Problem

AP (Mar. 25, 2015) — While distracted driving is not a new problem for teens, new research from the AAA Foundation for Traffic Safety says it&apos;s much more serious than previously thought. (March 25)
Video provided by AP

Many Don't Know They Have Alzheimer's, But Their Doctors Do

Newsy (Mar. 24, 2015) — According to a new study by the Alzheimer&apos;s Association, more than half of those who have the degenerative brain disease aren&apos;t told by their doctors.
Video provided by Newsy

A Quick 45-Minute Nap Can Improve Your Memory

Newsy (Mar. 23, 2015) — Researchers found those who napped for 45 minutes to an hour before being tested on information recalled it five times better than those who didn&apos;t.
Video provided by Newsy

Related Stories

Mar. 18, 2015 — People with a severe form of schizophrenia have major differences in their brain networks compared to others with schizophrenia, bipolar disorder and healthy individuals, a new study shows. ... full story

Dec. 9, 2014 — A novel drug target that could lead to the development of better antipsychotic medications has been discovered by researchers. Current treatment for patients with schizophrenia involves taking ... full story

Aug. 11, 2014 — The discovery of a new mechanism of drug action could lead to the next generation of drugs to treat schizophrenia. Affecting one per cent of the world's population, schizophrenia is a major ... full story

Nov. 2, 2012 — Researchers in Norway have found new support for their theory that cannabis use causes a temporary cognitive breakdown in non-psychotic individuals, leading to long-term psychosis. In an fMRI study, ... full story

Sep. 30, 2010 — New research has linked psychosis with an abnormal relationship between two signaling chemicals in the brain. The findings suggest a new approach to preventing psychotic symptoms, which could lead to ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.